share_log

Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target

Benzinga ·  Apr 24 00:29

Wedbush analyst Robert Driscoll reiterates Adicet Bio (NASDAQ:ACET) with a Outperform and maintains $5 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment